CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...

CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, muscle-invasive bladder cancer, according to results of a new phase III randomized trial.

FAYETTEVILLE, GA, UNITED STATES, January 26, 2026 /EINPresswire.com/ -- Postoperative recurrence remains the main ...

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: Many patients, including those whose cancer goes into ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

HBV, hepatitis B Researchers analyzed data from patients with chronic hepatitis B to identify predictors of relapse in those who discontinued NAs and determined if existing rules for stopping NA ...

Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...